Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Lyra Therapeutics, Inc. (LYRA) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/08/2023 8-K Quarterly results
Docs: "Lyra Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update -- ENLIGHTEN I Pivotal Phase 3 Trial of LYR-210 in Pre-Surgical Chronic Rhinosinusitis on Track to Complete Enrollment in the Coming Weeks, with Data Expected in 1H 2024 -- -- Initial Topline Results from BEACON Phase 2 Trial of LYR-220 in Post-Surgical CRS Now Anticipated Earlier Than Expected, in September 2023 -- WATERTOWN, Mass., August 8, 2023 -- Lyra Therapeutics, Inc. , a clinical-stage biotechnology company developing long-acting anti-inflammatory therapies for the localized treatment of chronic rhinosinusitis , today reported its financial results for the second quarter ended June 30, 2023 and provided a corporate update. “Lyra is approaching two exciting clinical milestones: We ex..."
07/14/2023 8-K Quarterly results
05/31/2023 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and E...
Docs: "Amendment No. 1 to Ninth Amended and Restated Investor Rights Agreement, by and among Lyra Therapeutics, Inc. and the Investors named therein",
"Form of Pre-Funded Warrant, together with a schedule of Pre-Funded Warrants, each, issued by Lyra Therapeutics, Inc. to the Investors set forth on such schedule",
"Form of Purchase Warrant, together with a schedule of Purchase Warrants, each, issued by Lyra Therapeutics, Inc. to the Investors set forth on such schedule",
"Securities Purchase Agreement, by and among Lyra Therapeutics, Inc. and the Investors named therein",
"Registration Rights Agreement, by and among Lyra Therapeutics, Inc. and the Investors named therein",
"Lyra Therapeutics Announces $50.0 Million Private Placement May 26, 2023 WATERTOWN, Mass., May 26, 2023 — Lyra Therapeutics, Inc. , a clinical-stage biotechnology company developing innovative therapies for the localized treatment of chronic rhinosinusitis, today announced that it has entered into a securities purchase agreement to sell securities in a private placement that is expected to result in gross proceeds of approximately $50.0 million, before deducting offering expenses. The closing of the private placement is subject to customary closing conditions and is expected to occur on or about May 31, 2023. Under the terms of the securities purchase agreement, Lyra has agreed to issue and sell approximately 17.7 million shares of the Company's common stock and pre-funded warrants to purc..."
05/12/2023 8-K Quarterly results
Docs: "Lyra Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update -- ENLIGHTEN I Pivotal Phase 3 Trial of LYR-210 in Pre-Surgical Chronic Rhinosinusitis on Track to Complete Enrollment, with Data Expected in 1H 2024 -- -- Data from BEACON Phase 2 Trial of LYR-220 in Post-Surgical CRS Anticipated Q4 2023 -- WATERTOWN, Mass., May 12, 2023 -- Lyra Therapeutics, Inc. , a clinical-stage biotechnology company developing innovative therapies for the localized treatment of chronic rhinosinusitis , today reported its financial results for the first quarter ended March 31, 2023 and provided a corporate update. “We've had a highly productive start to 2023, positioning us for anticipated key data readouts over the next 12 months,” said Maria Palasis, Ph.D., Pre..."
03/29/2023 8-K Quarterly results
11/16/2022 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "SIXTH AMENDMENT TO LEASE This Sixth Amendment to Lease is made as of November 14, 2022, by and between ARE-480 ARSENAL STREET, LLC, a Delaware limited liability company , and LYRA THERAPEUTICS, INC., a Delaware corporation . RECITALS A. Landlord and Tenant are parties to that certain Lease Agreement dated as of August 14, 2007, as amended by that certain First Amendment to Lease dated as of July 21, 2008, as further amended by that certain Second Amendment to Lease dated September 4, 2012, as further amended by that certain letter agreement dated as of September 4, 2012, as further amended by that certain Third Amendment to Lease dated as of September 6, 2013, as further amended by that certain letter agreement dated January 15, 2014, as further amended by that certain Fourth Amendment to ..."
11/08/2022 8-K Quarterly results
Docs: "Lyra Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update -- Company Prioritizing ENLIGHTEN I Pivotal Phase 3 Trial of LYR-210 in Chronic Rhinosinusitis ; Study Remains on Track, with Full Enrollment Anticipated mid-2023 -- -- Company to Manufacture All Clinical Trial Supply to Leverage its In-House Expertise and Capabilities; Temporarily Pausing Enrollment in ENLIGHTEN II Trial of LYR-210 in CRS to Align with Manufacturing Timelines; Enrollment Expected to Resume in the Third Quarter of 2023 -- WATERTOWN, Mass., November 8, 2022 /PRNewswire/ -- Lyra Therapeutics, Inc. , a clinical-stage biotechnology company developing novel, integrated drug and delivery solutions for the localized treatment of patients with chronic rhinosinusitis , today reported its fi..."
10/26/2022 8-K Quarterly results
09/12/2022 8-K Investor presentation
Docs: "Presentation Slide Deck"
08/09/2022 8-K Quarterly results
06/17/2022 8-K Quarterly results
05/31/2022 8-K Quarterly results
05/10/2022 8-K Quarterly results
Docs: "Lyra Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update In April 2022, secured $100.5 million in gross proceeds in an at-the-market, private placement of common stock that is expected to support two pivotal data readouts; cash runway extended until mid-2024"
04/13/2022 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits ...
Docs: "Ninth Amended and Restated Investor Rights Agreement, by and among Lyra Therapeutics, Inc. and the Investors named therein",
"Form of Common Stock Purchase Warrant, together with a schedule of Warrants, each dated April 12, 2022, issued by Lyra Therapeutics, Inc. to the Investors set forth on such schedule",
"Securities Purchase Agreement, by and among Lyra Therapeutics, Inc. and the Investors named therein",
"Registration Rights Agreement, by and among Lyra Therapeutics, Inc. and the Investors named therein",
"Lyra Therapeutics Announces $100.5 Million Private Placement WATERTOWN, Mass., April 8, 2022 - Lyra Therapeutics, Inc. , a clinical-stage therapeutics company leveraging its proprietary XTreo ™ platform to enable precise, sustained and local delivery of medications to the ear, nose and throat passages and other diseased tissues, today announced that it has entered into a securities purchase agreement to sell securities in a private placement that is expected to result in gross proceeds of approximately $100.5 million, before deducting offering expenses."
03/09/2022 8-K Quarterly results
02/18/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"First Amendment to the Employment Agreement, between Lyra Therapeutics, Inc. and Maria Palasis, Ph.D",
"Employment Agreement, between Lyra Therapeutics, Inc. and Harlan Waksal, M.D.",
"Lyra Therapeutics, Inc. 2020 Incentive Award Plan Performance Stock Option Grant Notice and Performance Stock Option Agreement issued to Maria Palasis, Ph.D. on February 16, 2022",
"Lyra Therapeutics, Inc. 2022 Inducement Award Plan Performance Stock Option Grant Notice and Performance Stock Option Agreement issued to Harlan Waksal, M.D. on February 16, 2022",
"Lyra Therapeutics, Inc. 2022 Inducement Award Plan"
11/09/2021 8-K Quarterly results
Docs: "Lyra Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update - LYR-210 Phase 3 ENLIGHTEN and LYR-220 Phase 2 BEACON studies on track to initiate around EOY - -"
09/15/2021 8-K Quarterly results
08/09/2021 8-K Quarterly results
06/11/2021 8-K Quarterly results
06/04/2021 8-K Quarterly results
05/28/2021 8-K Quarterly results
05/11/2021 8-K Quarterly results
04/13/2021 8-K Quarterly results
03/09/2021 8-K Quarterly results
12/07/2020 8-K Other Events, Financial Statements and Exhibits
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of report : December 7, 2020 LYRA THERAPEUTICS, INC. Delaware 001-39273 84-1700838 480 Arsenal Way Watertown, MA 02472 393-4600 N/A Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rule 13e-4 under the Exchange Act...",
"Lyra Therapeutics Announces Positive Topline Results for LANTERN Phase 2 Randomized Controlled Study of LYR-210 for the Treatment of Chronic Rhinosinusitis With and Without Nasal Polyps"
11/10/2020 8-K Quarterly results
Docs: "LYRA THERAPEUTICS, INC."
10/30/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of report : October 26, 2020 LYRA THERAPEUTICS, INC. Delaware 001-39273 84-1700838 480 Arsenal Way Watertown, MA 02472 393-4600 N/A Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rule 13e-4 under the Exchange Act..."
08/05/2020 8-K Quarterly results
07/24/2020 8-K Quarterly results
05/28/2020 8-K Quarterly results
Docs: "Lyra Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update WATERTOWN, MA - May 28, 2020 - Lyra Therapeutics, Inc. , a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat diseases, today reported financial results for the quarter ended March 31, 2020 and provided a corporate update. Key First Quarter 2020 and Subsequent Highlights"
05/05/2020 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of report : May 5, 2020 LYRA THERAPEUTICS, INC. Delaware 001-39273 84-1700838 480 Arsenal Way Watertown, MA 02472 393-4600 N/A Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rule 13e-4 under the Exchange Act ) Se...",
"Restated Certificate of Incorporation of Lyra Therapeutics, Inc",
"Amended and Restated Bylaws of Lyra Therapeutics, Inc"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy